CAMBRIDGE, Massachusetts, May 20, 2013 /PRNewswire/ --
Genomics Data App now available in BaseSpace Apps
Elsevier, a world-leading provider of scientific, medical and technical products and services, announces the launch of the Genomics Data app in collaboration with Illumina, a sequencing and array-based solutions provider for genetics research.
The app allows researchers to share large data sets in Illumina's BaseSpace cloud, where they can easily be reviewed and included in Elsevier's open access journal, Genomics Data. The BaseSpace app serves as a gateway, opening data stored in the cloud to the publishing environment for expert peer review and wide dissemination in the form of a professional publication.
"In genomic studies we often generate large data sets of tremendous value. Without a means to publish these data sets and get credit for them, they easily get lost," said John Quackenbush, Co-Editor-in-Chief of Genomics Data. "By working together with Illumina to develop a reviewing pipeline from BaseSpace to Genomics Data, we've created a simple way for researchers to make genomic data accessible to publication in a journal."
Through BaseSpace, authors and reviewers will also have additional access to analytical tools, further enhancing Genomics Data's peer review process. This enhanced review option can give an article attached to the data set added credibility because reviewers are in the position to reproduce the analysis that the authors did.
"Uploading genomic data to BaseSpace has reached critical mass. The innovative development of the Genomics Data App demonstrates how Elsevier is able to create new and unique opportunities for researcher collaboration," said Alex Dickinson, Senior Vice President, Cloud Genomics at Illumina.
To view the app, please register for free on:
# # #
About Genomics Data
Genomics Data is an open access journal and publishes high quality and standardized reports summarizing results of microarray or sequencing studies in all types of organisms. The genomic and functional genomic data/results are intended to serve as points of record that are enriched with data generation strategies and methods, data QC metrics, data analysis process and algorithms, biological interpretation and conclusions. All articles will be peer-reviewed and verified by the editorial team. For more information please visit http://www.journals.elsevier.com/genomics-data/.
Open Access Publishing at Elsevier
Elsevier has been providing open access publishing options since 2005. Today, researchers can choose to publish in over 1,500 hybrid journals as well as more than 39 full open access journals and these numbers will continue to grow rapidly. All of Elsevier's open access publications have been peer reviewed, ensuring that the broader community not only reads the latest research but that it is factual, original and of the highest quality and ethical standards. For more information about Elsevier's open access program, visit http://www.elsevier.com/openaccess
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect, Scopus, Reaxys, ClinicalKey and Mosby's Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group plc, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.